FRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol
phenylbutyrate) has been approved by the U.S. Food and Drug
Administration to treat certain urea cycle disorders (UCDs) in
people 2 years and older.
These inherited conditions involve a lack of enzymes that help
the body remove ammonia from the blood. In people with UCDs,
ammonia buildup can lead to coma, brain damage or death, the FDA
said Friday in a news release.
Ravicti is a liquid taken three times daily with meals. It's
been approved for people whose disorders cannot be managed by a
protein-restricted diet or amino acid supplements alone, the agency
Ravicti was compared to another UCD drug in a clinical study
involving 44 adults. The most common side effects of the new drug
were diarrhea, flatulence and headache.
Ravicti is marketed by Hyperion Therapeutics, based in South San
The U.S. National Library of Medicine has more about
NewsCopyright © 2013
HealthDay. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.